Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism
Status:
Terminated
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The development of clots is a potentially deadly complication in many cancer patients. The
current optimal treatment is unknown. Evidence supporting the effectiveness of the use of
Inferior Vena Caval Filters is lacking. This study will compare the two standard of care
treatment options: anticoagulation with or without a inferior vena cava filter. The
anticoagulation medication chosen will be Arixtra and it will be given once a day as an
injection. Patients will be called at various intervals to monitor their signs and symptoms
of new thromboembolisms.